Stabilized formulations containing anti-DLL4 antibodies
US9675692B2 · kind B2 · utility
0Cited by
20References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 31, 2013 |
| Grant date | Jun 13, 2017 |
| Priority date | — |
| Expiry date | Dec 20, 2033 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides pharmaceutical formulations comprising an antibody that specifically binds to human delta-like ligand 4 (Dll4). The formulations may contain, in addition to an anti-Dll4 antibody, a phosphate buffer, an organic cosolvent, a disaccharide, and a salt. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months and after being subjected to thermal and other physical stress.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.